Parkwood LLC Acquires 194,711 Shares of Sanofi $SNY

Key Points

• Parkwood LLC increased its stake in Sanofi by 76.1% in Q1, owning 450,428 shares valued at approximately $24.98 million, making it the 8th largest holding in their portfolio.
• Sanofi reported earnings of $0.90 EPS for the most recent quarter, missing the consensus estimate of $0.96, while revenue was $11.34 billion, exceeding analyst expectations.
• Several hedge funds have increased their positions in Sanofi, including Mirae Asset Global Investments, which raised its stake by 124.0%, highlighting increased institutional interest in the company.

Parkwood LLC lifted its stake in Sanofi (NASDAQ:SNY - Free Report) by 76.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 450,428 shares of the company's stock after acquiring an additional 194,711 shares during the period. Sanofi accounts for 2.3% of Parkwood LLC's portfolio, making the stock its 8th largest position. Parkwood LLC's holdings in Sanofi were worth $24,980,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in SNY. Accent Capital Management LLC purchased a new position in Sanofi during the 1st quarter worth $29,000. Eastern Bank grew its position in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after purchasing an additional 300 shares during the last quarter. Banque Transatlantique SA purchased a new stake in Sanofi during the 1st quarter worth approximately $33,000. Golden State Wealth Management LLC grew its position in Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares during the last quarter. Finally, Brentview Investment Management LLC purchased a new stake in Sanofi during the 1st quarter worth approximately $42,000. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

Shares of NASDAQ SNY traded up $0.65 during trading on Tuesday, reaching $47.45. 2,431,668 shares of the company traded hands, compared to its average volume of 2,607,123. The firm's fifty day simple moving average is $48.75 and its 200 day simple moving average is $51.28. The stock has a market cap of $116.51 billion, a P/E ratio of 11.41, a PEG ratio of 1.11 and a beta of 0.51. Sanofi has a 12-month low of $44.73 and a 12-month high of $60.12. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business's quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.73 EPS. As a group, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the topic of several research analyst reports. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.